CALGARY, Alberta, Jan. 20, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on BioCurex, Inc. (OTCBB:BOCX). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php
About BioCurex, Inc. (OTCBB:BOCX)
BioCurex, Inc. (OTCBB:BOCX) is a development stage diagnostics company focusing on development and commercialization of products for the early detection, diagnosis, and monitoring of recurrence of cancer. BioCurex has developed a blood test that can detect the presence of cancer in humans and companion animals using a new cancer marker named RECAF.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.
CONTACT: Skymark Research
Dylan Boyle
202-657-6249
info@skymarkresearch.com
